Gadolinium inhibits prostate cancer PC3 cell migration and suppresses osteoclast differentiation in vitro

Cell Biology International

Volumn 35, Issue 11, 2011, Pages 1159-1167

  Wang, Peng ^a   Zou, Xiao Min ^a   Huang, Jian ^a   Zhang, Tian Lan ^a   Wang, Kui ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Differentiation; Gadolinium; Migration; Osteoclast; Prostate cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANNEXIN; GADOLINIUM CHLORIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PERTUSSIS TOXIN; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL ASSAY; CELL DIFFERENTIATION; CELL MIGRATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; OSTEOCLAST; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GADOLINIUM; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED ICR; MICROSCOPY, CONFOCAL; OSTEOCLASTS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLIUM SALTS; THIAZOLES; WOUND HEALING;

EID: 80054981630     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20100870     Document Type: Article

References (40)

1. Angelucci A, Schenone S, Gravina GL, Muzi P, Festuccia C, Vicentini C et al. Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer 2006;42:2838-45.
2. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008;68:92-104.
3. Atherton ND, Gaitonde MD, Totten JW, Davies PN, Pratt RD. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone disease. United States Patent 2007:0048390.
4. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-9.
5. Barta CA, Sachs-Barrable K, Jia J, Thompson KH, Wasan KM, Orvig C. Lanthanide containing compounds for therapeutic care in bone resorption disorders. Dalton Trans 2007;43: 5019-30.
6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
7. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009;310:71-81.
8. Chen L, He HY, Li HM, Zheng J, Heng WJ, You JF et al. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 2004;215:239-47.
9. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005;173:10-20.
10. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
11. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006;78:1784-93.
12. Fricker SP. The therapeutic application of lanthanides. Chem Soc Rev 2006;35:524-33.
13. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6s.
14. Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998;273:1839-42.
15. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta 2007;1771:883-92.
16. Harlozinska A. Progress in molecular mechanisms of tumor metastasis and angiogenesis. Anticancer Res 2005;25:3327-33.
17. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
18. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010;116:1406-18.
19. Kapoor S. Lanthanum and its rapidly emerging role as an anti- carcinogenic agent. J Cell Biochem 2009;106:193.
20. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118:3051-64.
21. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
22. Luo XG, Ding Y, Zhou QF, Ye L, Wang SZ, Xi T. SET and MYND domain- containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells. J Biosci Bioeng 2007;103:444-50.
23. Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 2006;16:466-76.
24. Martin GS. Cell signaling and cancer. Cancer Cell 2003;4:167-74.
25. Moretti RM, Monagnani MM, van Groeninghen JC, Motta M, Limonta P. Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr Relat Cancer 2003;10:161-7.
26. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010;37(Suppl. 1):S53-65.
27. Pienta KJ, Loberg R. The 'emigration, migration, and immigration' of prostate cancer. Clin Prostate Cancer 2005;4:24-30.
28. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 2008;3:e3627.
29. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008;34:92-101.
30. Shen KH, Hung SH, Yin LT, Huang CS, Chao CH, Liu CL et al. Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. Mol Cell Biochem 2010;333:279-91.
31. Shi YL, Wang LW, Huang J, Gou BD, Zhang TL, Wang K. Lanthanum suppresses osteoblastic differentiation via pertussis toxin-sensitive G protein signaling in rat vascular smooth muscle cells. J Cell Biochem 2009;108:1184-91.
32. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
33. Singh LS, Berk M, Oates R, Zhao Z, Tan H, Jiang Y, et al. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst 2007;99:1313-27.
34. Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004;91:706-17.
35. Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 2008;66:180-3.
36. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12:6285s-90s.
37. Virk MS, Petrigliano FA, Liu NQ, Chatziioannou AF, Stout D, Kang CO, et al. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone 2009;44:160-7.
38. Wang X, Yuan L, Huang J, Zhang TL, Wang K. Lanthanum enhances in vitro osteoblast differentiation via pertussis toxin-sensitive Gi protein and ERK signaling pathway. J Cell Biochem 2008;105:1307-15.
39. Webster TJ, Massa-Schlueter EA, Smith JL, Slamovich EB. Osteoblast response to hydroxyapatite doped with divalent and trivalent cations. Biomaterials 2004;25:2111-21.
40. Ye J, Yuan L. Inhibition of p38 MAPK reduces tumor conditioned medium- induced angiogenesis in co-cultured human umbilical vein endothelial cells and fibroblasts. Biosci Biotechnol Biochem 2007;71:1162-9.